About the Program

The Hematologic Malignancies Program of the Mayo Clinic Cancer Center conducts research on cancers of the blood and bone marrow.

The program focuses on the genetic, molecular and cellular basis of hematologic malignancies and the translation of these findings into novel clinical trials and new therapeutic treatment options.

The Hematologic Malignancies Program has three main research goals:

  • Investigating the epidemiology and mechanisms of progression for hematologic malignancies
  • Characterizing the cell biology and molecular nature of hematologic malignancies to identify new therapeutic targets
  • Developing new therapies for hematologic malignancies

To accomplish these goals, the Hematologic Malignancies Program is organized into four disease-oriented groups:

  • Acute leukemia and myeloid neoplasms
  • Chronic lymphocytic leukemia
  • Lymphoma
  • Myeloma/dysproteinemia

Researchers in these disease-oriented groups explore all facets of hematologic malignancies, including the causes and genetics behind cancers of the blood, how cancer progresses, and new treatments, such as immune targeting and gene therapy.

The Hematologic Malignancies Program conducts research at all three Mayo Clinic campuses — in Phoenix/Scottsdale, Arizona; Jacksonville, Florida; and Rochester, Minnesota.

Read more about the cancer research taking place in the Hematologic Malignancies Program.

SPORE research grants

The Hematologic Malignancies Program also participates in two Specialized Programs of Research Excellence (SPOREs):

Program leadership

The Hematologic Malignancies Program is directed by Stephen M. Ansell, M.D., Ph.D.; Leif Bergsagel, M.D.; and Asher A. Chanan-Khan, M.D., M.B.B.S.

  • Dr. Ansell, a hematologist and an oncologist, is a professor of medicine in the Mayo Clinic College of Medicine and Science in Rochester, Minnesota. Dr. Ansell's research focuses on understanding the biology of B-cell malignancies, including Hodgkin's lymphoma Waldenstrom macroglobulinemia and non-Hodgkin's lymphoma, and on exploring the role of the tumor microenvironment in supporting cancer cell growth and survival.
  • Dr. Bergsagel, an oncologist, is a professor of medicine in the Mayo Clinic College of Medicine and Science in Phoenix, Arizona. Dr. Bergsagel studies the molecular pathogenesis of multiple myeloma and its precursor, monoclonal gammopathy of undetermined significance (MGUS).
  • Dr. Chanan-Khan, a hematologist, is a professor of medicine in the Mayo Clinic College of Medicine and Science in Jacksonville, Florida. Dr. Chanan-Khan's research is dedicated to advancing and discovering treatments for patients with chronic lymphocytic leukemia, Waldenstrom macroglobulinemia and multiple myeloma.